Prognostic Value of Purinergic Receptors in Ovarian Cancer and Analysis of Tumor Immune Infiltration
Objective To construct a prognostic model of purinergic receptor family genes in serous ovarian cancer(OV),and to analyze the relationship between gene expression and immune cell infiltration and commonly used chemotherapeutic drugs.Methods The expression profile data and clinical information of 15 purinergic receptor family genes in databases such as the Cancer Genome Atlas(TCGA)were downloaded.LASSO regression analysis was used to screen genes related to the survival of OV patients.Patients were grouped according to the risk value and Kaplan-Meier Plotter was used to analyze the survival of key genes.Multivariate Cox regression analysis was used to construct a prognostic model based on TCGA-OV data set,and the nomogram and calibration curve were drawn.Immune infiltration analysis was performed using TIMER and xCell algorithms.TIDE algorithm was used to analyze the correlation between gene expression and immune checkpoint blockade(ICB)treatment.Drug sensitivity analysis was performed using the TCGA combined with Genomics of Drug Sensitivity in Cancer(GDSC)database.Results Six purinergic receptor family genes screened by LASSO regression analysis were related to the prognosis of OV patients.Multivariate Cox regression analysis showed that P2RX6,P2RY12,P2RY14,age and race were independent prognostic factors for OV patients(P＜0.05).The expression of P2RX6 and P2RY14 was down-regulated in OV(P＜0.05).The expression of P2RY14 was not only related to PDCD1,CTLA4,TIGIT and other immune checkpoints,but also negatively correlated with the half inhibitory concentration(IC5o)of paclitaxel,cisplatin,cyclophosphamide and docetaxel.P2RY14-related genes were mainly involved in biological processes such as immune cell activation,differentiation,and proliferation.Conclusion Based on the TCGA database,the prognostic model of OV patients is constructed.After screening,P2RY14 can be used as an independent risk factor for the prognosis of OV patients,which can provide new ideas and directions for guiding the immunotherapy of OV.
万方数据
维普
